Wakelin McNeel
Psychiatry · Rosemead, CANPI 1730192931
Payments from drug & device makers
Across 386 payments — averaging $28,557 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$6.8M
- AbbVie$2.7M
- E.r. Squibb & Sons, L.L.C.$1.2M
- Boehringer Ingelheim$211K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$44K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21K
- plus $56K from 9 others
Across 10 payments — averaging $242.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- Acadia Pharmaceuticals Inc$1K
What the payments were for
- Food & beverage$145100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 190 | $6,805,997 |
| AbbVie(2 entities) | 125 | $2,701,620 |
| E.r. Squibb & Sons, L.L.C. | 11 | $1,183,569 |
| Boehringer Ingelheim | 13 | $210,759 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $44,138 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $20,738 |
| Neurocrine Biosciences, Inc. | 22 | $15,061 |
| Acadia Pharmaceuticals Inc | 1 | $14,340 |
| Biogen | 2 | $14,206 |
| Boehringer Ingelheim RCV GmbH & Co KG | 3 | $8,865 |
| Mallinckrodt LLC | 3 | $2,040 |
| Avanir Pharmaceuticals, Inc. | 1 | $1,500 |
| Johnson & Johnson | 1 | $26 |
| Lundbeck LLC | 1 | $22 |
| Alkermes, Inc. | 1 | $20 |
How this compares
$11,022,902 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 11 | $6,377 |
| Lamotrigine | 21 | $48 |
| Omeprazole | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Rosemead
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Donald AndersonBanning$10.5M
- Gustavo AlvaOrange$9.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.